Skye Bioscience, Common Stock Probability of Future Stock Price Finishing Under 3.65
Skye Bioscience,'s future price is the expected price of Skye Bioscience, instrument. It is based on its current growth rate as well as the projected cash flow expected by the investors. This tool provides a mechanism to make assumptions about the upside potential and downside risk of Skye Bioscience, Common performance during a given time horizon utilizing its historical volatility. Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing.
Please specify Skye Bioscience,'s target price for which you would like Skye Bioscience, odds to be computed.
Skye |
Skye Bioscience, Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Skye Bioscience, for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Skye Bioscience, Common can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Skye Bioscience, is not yet fully synchronised with the market data | |
| Skye Bioscience, has some characteristics of a very speculative penny stock | |
| Skye Bioscience, Common currently holds 4.62 M in liabilities with Debt to Equity (D/E) ratio of 0.84, which is about average as compared to similar companies. Skye Bioscience, Common has a current ratio of 0.89, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Note, when we think about Skye Bioscience,'s use of debt, we should always consider it together with its cash and equity. | |
| Net Loss for the year was (37.64 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Skye Bioscience, Common currently holds about 2.93 M in cash with (13.95 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.01. | |
| Skye Bioscience, has a frail financial position based on the latest SEC disclosures | |
| Over 85.0% of Skye Bioscience, shares are owned by institutional investors |
Skye Bioscience, Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Skye Stock often depends not only on the future outlook of the current and potential Skye Bioscience,'s investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Skye Bioscience,'s indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 7 M | |
| Cash And Short Term Investments | 1.3 M |
Skye Bioscience, Technical Analysis
Skye Bioscience,'s future price can be derived by breaking down and analyzing its technical indicators over time. Skye Stock technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of Skye Bioscience, Common. In general, you should focus on analyzing Skye Stock price patterns and their correlations with different microeconomic environments and drivers.
Skye Bioscience, Predictive Forecast Models
Skye Bioscience,'s time-series forecasting models is one of many Skye Bioscience,'s stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary Skye Bioscience,'s historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.
Things to note about Skye Bioscience, Common
Checking the ongoing alerts about Skye Bioscience, for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for Skye Bioscience, Common help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
| Skye Bioscience, is not yet fully synchronised with the market data | |
| Skye Bioscience, Common currently holds 4.62 M in liabilities with Debt to Equity (D/E) ratio of 0.84, which is about average as compared to similar companies. Skye Bioscience, Common has a current ratio of 0.89, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Note, when we think about Skye Bioscience,'s use of debt, we should always consider it together with its cash and equity. | |
| Net Loss for the year was (37.64 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Skye Bioscience, Common currently holds about 2.93 M in cash with (13.95 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.01. | |
| Skye Bioscience, has a frail financial position based on the latest SEC disclosures | |
| Over 85.0% of Skye Bioscience, shares are owned by institutional investors |
Check out Skye Bioscience, Backtesting, Skye Bioscience, Valuation, Skye Bioscience, Correlation, Skye Bioscience, Hype Analysis, Skye Bioscience, Volatility, Skye Bioscience, History as well as Skye Bioscience, Performance. You can also try the Commodity Channel module to use Commodity Channel Index to analyze current equity momentum.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Skye Bioscience,. If investors know Skye will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Skye Bioscience, listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Skye Bioscience, Common is measured differently than its book value, which is the value of Skye that is recorded on the company's balance sheet. Investors also form their own opinion of Skye Bioscience,'s value that differs from its market value or its book value, called intrinsic value, which is Skye Bioscience,'s true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Skye Bioscience,'s market value can be influenced by many factors that don't directly affect Skye Bioscience,'s underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Skye Bioscience,'s value and its price as these two are different measures arrived at by different means. Investors typically determine if Skye Bioscience, is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Skye Bioscience,'s price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.